<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="38bdc7bd-c714-452e-910a-c4afa36ef1f8"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">QULIPTA</content>
      <content styleCode="bold"> safely and effectively. See full prescribing information for </content>
      <content styleCode="bold">QULIPTA</content>
      <content styleCode="bold">. </content>
      <br/>
      <content styleCode="bold">  </content>
      <br/>
      <content styleCode="bold">QULIPTA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (atogepant) tablets, for oral use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: </content>
      <content styleCode="bold">2021</content>
      <br/>
   </title>
   <effectiveTime value="20250321"/>
   <setId root="8c8ab8f4-32bd-497a-befa-70c8a51d8d52"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="078458370" root="1.3.6.1.4.1.519.1"/>
            <name>AbbVie Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="689a450a-d8cb-49c7-8952-008b056acf2e"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250327"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7095" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Qulipta</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atogepant</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7CRV8RR151" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATOGEPANT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7CRV8RR151" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATOGEPANT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O03S90U1F2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VITAMIN E POLYETHYLENE GLYCOL SUCCINATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-7095-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215206" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A;10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7096" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Qulipta</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atogepant</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7CRV8RR151" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATOGEPANT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7CRV8RR151" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATOGEPANT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O03S90U1F2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VITAMIN E POLYETHYLENE GLYCOL SUCCINATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-7096-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="4"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-7096-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211006"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215206" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A30</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-7094" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Qulipta</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atogepant</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7CRV8RR151" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATOGEPANT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7CRV8RR151" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATOGEPANT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O03S90U1F2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VITAMIN E POLYETHYLENE GLYCOL SUCCINATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-7094-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="4"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0074-7094-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211006"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215206" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A60</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="9165c4ea-121b-4667-a459-a64904c39172"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43683-2" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col width="367"/>
                           <col width="367"/>
                           <tbody>
                              <tr>
                                 <td/>
                                 <td align="center"/>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#_5_2_Hypertension">5.2</linkHtml>, <linkHtml href="#_5_3_Raynaud_s_Phenomenon">5.3</linkHtml>)</td>
                                 <td>
		     
	3/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="d3483b04-8ee4-4ba1-b1f1-1a589c4f5349"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
		     
	<content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>QULIPTA is indicated for the preventive treatment of migraine in adults.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="e66a7595-a3da-4bb9-8a49-1c90e817886c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
		     
	<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>QULIPTA is taken orally with or without food. (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>)<br/>
                           </item>
                           <item>For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily. (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>)<br/>
                           </item>
                           <item>For chronic migraine, the recommended dosage is 60 mg taken once daily. (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>)<br/>
                           </item>
                           <item>Severe Renal Impairment or End-Stage Renal Disease (<linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>, <linkHtml href="#_8_6_Renal_Impairment">8.6</linkHtml>):<list listType="unordered" styleCode="Circle">
                                 <item>Episodic migraine: 10 mg once daily. <br/>
                                 </item>
                                 <item>Chronic migraine: Avoid use.</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Recommended_Dosage">
                     <id root="d3eb7a9b-75db-41cc-b3d8-fba3ec3a2db5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1</content>
                        <content styleCode="bold">
		     
	Recommended Dosage</content>
                     </title>
                     <text>
                        <paragraph>QULIPTA is taken orally with or without food.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Episodic Migraine</content>
                        </paragraph>
                        <paragraph>The recommended dosage of QULIPTA for episodic migraine is 10 mg, 30 mg, or 60 mg taken once daily. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Chronic Migraine</content>
                        </paragraph>
                        <paragraph>The recommended dosage of QULIPTA for chronic migraine is 60 mg taken once daily. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Dosage_Modifications">
                     <id root="b13cad71-05c5-409a-910d-cba2229764a7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2</content>
                        <content styleCode="bold">
		     
	Dosage </content>
                        <content styleCode="bold">Modification</content>
                        <content styleCode="bold">s</content>
                        <content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph>Dosing modifications for concomitant use of specific drugs and for patients with renal impairment are provided in Table 1.</paragraph>
                        <table>
                           <caption>Table 1: Dosage Modifications for Drug Interactions and for Specific Populations</caption>
                           <col width="381"/>
                           <col width="148"/>
                           <col width="148"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Dosage Modifications</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Recommended </content>
                                    <content styleCode="bold">Once Daily</content>
                                    <br/>
                                    <content styleCode="bold">Dos</content>
                                    <content styleCode="bold">ag</content>
                                    <content styleCode="bold">e</content>
                                    <content styleCode="bold"> for</content>
                                    <br/>
                                    <content styleCode="bold">Episodic Migraine</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Usage and</content>
                                    <br/>
                                    <content styleCode="bold">Recommended</content>
                                    <br/>
                                    <content styleCode="bold">Once Daily</content>
                                    <br/>
                                    <content styleCode="bold">Dos</content>
                                    <content styleCode="bold">ag</content>
                                    <content styleCode="bold">e</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">for</content>
                                    <br/>
                                    <content styleCode="bold">Chronic Migraine</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                                    <content styleCode="bold">Concomitant Drug </content>
                                    <content styleCode="bold italics">[see Drug Interactions (</content>
                                    <content styleCode="bold italics">
                                       <linkHtml href="#_7_DRUG_INTERACTIONS">7</linkHtml>
                                    </content>
                                    <content styleCode="bold italics">)]</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Strong CYP3A4 Inhibitors<content styleCode="italics"> (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_7_1_CYP3A4_Inhibitors">7.1</linkHtml>
                                    </content>
                                    <content styleCode="italics">)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Avoid use</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Strong, Moderate, or Weak CYP3A4 Inducers <content styleCode="italics">(</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_7_2_CYP3A4_Inducers">7.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30 mg or 60 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Avoid use</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">OATP Inhibitors <content styleCode="italics">(</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_7_3_OATP_Inhibitors">7.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10 mg or 30 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30 mg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                                    <content styleCode="bold">Renal Impairment </content>
                                    <content styleCode="bold italics">[see Use in Specific Populations</content>
                                    <content styleCode="bold italics"> </content>
                                    <content styleCode="bold italics">(</content>
                                    <content styleCode="bold italics">
                                       <linkHtml href="#_8_USE_IN">8</linkHtml>
                                    </content>
                                    <content styleCode="bold italics">)</content>
                                    <content styleCode="bold italics">]</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Severe Renal Impairment and End-Stage Renal Disease (CLcr &lt;30 mL/min) <content styleCode="italics">(</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_8_6_Renal_Impairment">8.6</linkHtml>
                                    </content>
                                    <content styleCode="italics">)</content> </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Avoid use</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="52c85f3f-a97f-4c6f-8b0f-a76f09e6bb07"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
		     
	<content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>QULIPTA 10 mg is supplied as white to off-white, round biconvex tablets debossed with “A” and “10” on one side.</paragraph>
                  <paragraph>QULIPTA 30 mg is supplied as white to off-white, oval biconvex tablets debossed with “A30” on one side.</paragraph>
                  <paragraph>QULIPTA 60 mg is supplied as white to off-white, oval biconvex tablets debossed with “A60” on one side.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 10 mg, 30 mg, and 60 mg. (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Hyperlink4">
               <id root="a84f815b-64c3-43c8-a873-0af71acee72a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
		     
	<content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA. Reactions have included anaphylaxis and dyspnea <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#hyperlink5_1">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> Patients with a history of hypersensitivity to atogepant or to any of the components of QULIPTA.  (<linkHtml href="#Hyperlink4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="53df2972-f2b7-4dbd-8771-6955926801be"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity Reactions: If a hypersensitivity reaction occurs, discontinue QULIPTA and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis and dyspnea. These reactions can occur days after administration. (<linkHtml href="#hyperlink5_1">5.1</linkHtml>)<br/>
                           </item>
                           <item>Hypertension: New-onset or worsening of pre-existing hypertension may occur. (<linkHtml href="#_5_2_Hypertension">5.2</linkHtml>)<br/>
                           </item>
                           <item>Raynaud’s phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur. (<linkHtml href="#_5_3_Raynaud_s_Phenomenon">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="hyperlink5_1">
                     <id root="b3931ae5-9572-4204-b7f2-70eb69e396b4"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
                        <content styleCode="bold">
		     
	Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_2_Postmarketing_Experience">6.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="italics">
                              <linkHtml href="#Hyperlink4">4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Hypertension">
                     <id root="b6e95a91-3b5b-404d-a22c-cefeaccd9ed8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold">
		     
	Hyper</content>
                        <content styleCode="bold">tension</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including QULIPTA, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. QULIPTA was discontinued in many of the reported cases.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor patients treated with QULIPTA for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of QULIPTA is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Raynaud_s_Phenomenon">
                     <id root="2e00669f-b606-4b9b-855c-e0d892af6d38"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">3</content>
		     
	<content styleCode="bold">Raynaud’s Phenomenon</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including QULIPTA. In reported cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">QULIPTA should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c7907948-13fe-47cb-8c52-03b365550b17"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#hyperlink5_1">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Hypertension <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_2_Hypertension">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Raynaud’s Phenomenon <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_3_Raynaud_s_Phenomenon">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="918f88ab-888e-4704-a7c8-904260c05fb7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
                        <content styleCode="bold">
		     
	Clinical </content>
                        <content styleCode="bold">Trials </content>
                        <content styleCode="bold">Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of QULIPTA was evaluated in 2657 patients with migraine who received at least one dose of QULIPTA.  Of these, 1225 patients were exposed to QULIPTA for at least 6 months, and 826 patients were exposed for 12 months.</paragraph>
                        <paragraph>In the 12-week, placebo-controlled clinical studies (Studies 1, 2, and 3), 314 patients received at least one dose of QULIPTA 10 mg once daily, 411 patients received at least one dose of QULIPTA 30 mg once daily, 678 patients received at least one dose of QULIPTA 60 mg once daily, and 663 patients received placebo <content styleCode="italics">[see </content>
                           <content styleCode="italics">Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_CLINICAL_STUDIES">14</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>. Approximately 88% were female, 75% were White, 13% were Black, 10% were Asian, and 10% were of Hispanic or Latino ethnicity. The mean age at study entry was 41 years (range 18 to 74 years).</paragraph>
                        <paragraph>The most common adverse reactions (incidence at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence. </paragraph>
                        <paragraph>Table 2 summarizes the adverse reactions that occurred during Studies 1, 2, and 3.</paragraph>
                        <table>
                           <caption>Table 2: Adverse Reactions Occurring with an Incidence of At Least 2% for QULIPTA and Greater than Placebo in Studies 1, 2, and 3<sup>*</sup>
                           </caption>
                           <col width="156"/>
                           <col width="99"/>
                           <col width="123"/>
                           <col width="123"/>
                           <col width="123"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N= </content>
                                    <content styleCode="bold">663</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <content styleCode="bold"> </content>
                                    <br/>
                                    <content styleCode="bold">10 mg</content>
                                    <br/>
                                    <content styleCode="bold">(N=314)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <content styleCode="bold"> </content>
                                    <br/>
                                    <content styleCode="bold">30 mg</content>
                                    <br/>
                                    <content styleCode="bold">(N=411)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <content styleCode="bold"> </content>
                                    <br/>
                                    <content styleCode="bold">60 mg</content>
                                    <br/>
                                    <content styleCode="bold">(N=</content>
                                    <content styleCode="bold">678</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Fatigue/Somnolence</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Decreased Appetite</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Dizziness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* 10 mg and 30 mg incidence from Studies 1 and 2; 60 mg pooled incidence from Studies 1, 2, and 3. </paragraph>
                        <paragraph>The adverse reactions that most commonly led to discontinuation of QULIPTA in these studies were nausea (0.6%), constipation (0.5%), and fatigue/somnolence (0.2%). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Liver Enzyme Elevations</content>
                        </paragraph>
                        <paragraph>In Study 1, Study 2, and Study 3, the rate of transaminase elevations over 3 times the upper limit of normal was similar between patients treated with QULIPTA (0.9%) and those treated with placebo (1.2%). However, there were cases with transaminase elevations over 3 times the upper limit of normal that were temporally associated with QULIPTA treatment; these were asymptomatic and resolved within 8 weeks of discontinuation. There were no cases of severe liver injury or jaundice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Decreases </content>
                           <content styleCode="underline">in Body Weight</content>
                        </paragraph>
                        <paragraph>In Study 1, Study 2, and Study 3, the proportion of patients with a weight decrease of at least 7% at any point was 2.5% for placebo, 3.8% for QULIPTA 10 mg, 3.2% for QULIPTA 30 mg, and 5.3% for QULIPTA 60 mg. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_6_2_Postmarketing_Experience">
                     <id root="ccafcb1e-baf7-4854-a41d-ba597e121079"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
                        <content styleCode="bold">
		     
	Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of QULIPTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders</content>: Hypersensitivity (e.g., anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema) <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="italics">
                              <linkHtml href="#Hyperlink4">4</linkHtml>
                           </content>
                           <content styleCode="italics">) and Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#hyperlink5_1">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content> Hypertension <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_2_Hypertension">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, Raynaud’s phenomenon <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_3_Raynaud_s_Phenomenon">5.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_7_DRUG_INTERACTIONS">
               <id root="ada1329e-1d03-4172-9c65-97e192cd7062"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7</content>
                  <content styleCode="bold">
		     
	DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Recommended dosage modifications: </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Strong CYP3A4 Inhibitor (<linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>, <linkHtml href="#_7_1_CYP3A4_Inhibitors">7.1</linkHtml>):<br/>○ Episodic migraine: 10 mg once daily. <br/>○ Chronic migraine: avoid use.<br/>
                           </item>
                           <item>Strong, Moderate, or Weak CYP3A4 Inducers (<linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>, <linkHtml href="#_7_2_CYP3A4_Inducers">7.2</linkHtml>):<br/>○ Episodic migraine: 30 mg or 60 mg once daily.<br/>○ Chronic migraine: avoid use. <br/>
                           </item>
                           <item>OATP Inhibitors (<linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>, <linkHtml href="#_7_3_OATP_Inhibitors">7.3</linkHtml>):<br/>○ Episodic migraine: 10 mg or 30 mg once daily. <br/>○ Chronic migraine: 30 mg once daily.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1_CYP3A4_Inhibitors">
                     <id root="cd682de8-5c5b-4744-ad25-a8d390755486"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
		     
	<content styleCode="bold">CYP3A4 Inhibitors </content>
                     </title>
                     <text>
                        <paragraph>Coadministration of QULIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of atogepant in healthy subjects <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. For episodic migraine, the recommended dosage of QULIPTA with concomitant use of strong CYP3A4 inhibitors is 10 mg once daily. For chronic migraine, avoid concomitant use of strong CYP3A4 inhibitors with QULIPTA <content styleCode="italics">[see Dosage and Administration</content>
                           <content styleCode="italics"> (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>. No dosage adjustment of QULIPTA is needed with concomitant use of moderate or weak CYP3A4 inhibitors.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_2_CYP3A4_Inducers">
                     <id root="3606fe41-4e34-4332-a3e1-1344ac11a00b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2</content>
		     
	<content styleCode="bold">CYP3A4 Inducers</content>
                     </title>
                     <text>
                        <paragraph>Coadministration of QULIPTA with steady state rifampin, a strong CYP3A4 inducer, resulted in a significant decrease in exposure of atogepant in healthy subjects <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Concomitant administration of QULIPTA with moderate inducers of CYP3A4 can also result in decreased exposure of atogepant. Coadministration of QULIPTA with steady-state topiramate, a weak CYP3A4 inducer, resulted in decreased exposure of atogepant in healthy<content styleCode="italics"> </content>subjects<content styleCode="italics"> </content>
                           <content styleCode="italics">[see Clinical Phar</content>
                           <content styleCode="italics">macology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>For episodic migraine, the recommended dosage of QULIPTA with concomitant use of strong, moderate, or weak CYP3A4 inducers is 30 mg or 60 mg once daily <content styleCode="italics">[see Dosage and Administration</content>
                           <content styleCode="italics"> (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.  </paragraph>
                        <paragraph>For chronic migraine, avoid concomitant use of strong, moderate, or weak CYP3A4 inducers with QULIPTA <content styleCode="italics">[see Dosage and Administration</content>
                           <content styleCode="italics"> (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_3_OATP_Inhibitors">
                     <id root="9298b25f-f8b3-4849-bd9b-2e16255e47b5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7</content>
                        <content styleCode="bold">.3</content>
		     
	<content styleCode="bold">OATP Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>Coadministration of QULIPTA with single dose rifampin, an OATP inhibitor, resulted in a significant increase in exposure of atogepant in healthy subjects <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. For episodic migraine, the recommended dosage of QULIPTA with concomitant use of OATP inhibitors is 10 mg or 30 mg once daily. For chronic migraine, the recommended dosage of QULIPTA with concomitant use of OATP inhibitors is 30 mg once daily <content styleCode="italics">[see Dosage and Administration</content>
                           <content styleCode="italics"> (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_8_USE_IN">
               <id root="2e30b506-569d-4929-90f6-dc29cc3ba430"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
                  <content styleCode="bold">
		     
	USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy: Based on animal data, may cause fetal harm. (<linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>)<br/>
                           </item>
                           <item>Avoid use in patients with severe hepatic impairment. (<linkHtml href="#_8_7_Hepatic_Impairment">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1_Pregnancy">
                     <id root="96101210-99a0-4fb2-8435-2b852dc30a74"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
                        <content styleCode="bold">
		     
	Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically <content styleCode="italics">[see </content>
                           <content styleCode="italics">Data</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk </content>
                        </paragraph>
                        <paragraph>Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal </content>
                           <content styleCode="italics">Data</content>
                        </paragraph>
                        <paragraph>Oral administration of atogepant (0, 5, 15, 125, or 750 mg/kg/day) to pregnant rats during the period of organogenesis resulted in decreases in fetal body weight and in skeletal ossification at the two highest doses tested (125 and 750 mg/kg),  which were not associated with maternal toxicity.  At the no-effect dose (15 mg/kg/day) for adverse effects on embryofetal development, plasma exposure (AUC) was approximately 4 times that in humans at the maximum recommended human dose (MRHD) of 60 mg/day.</paragraph>
                        <paragraph>Oral administration of atogepant (0, 30, 90, or 130 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in an increase in fetal visceral and skeletal variations at the highest dose tested (130 mg/kg/day), which was associated with minimal maternal toxicity. At the no-effect dose (90 mg/kg/day) for adverse effects on embryofetal development, plasma exposure (AUC) was approximately 3 times that in humans at the MRHD. </paragraph>
                        <paragraph>Oral administration of atogepant (0, 15, 45, or 125 mg/kg/day) to rats throughout gestation and lactation resulted in decreased pup body weight at the highest dose tested (125 mg/kg/day), which persisted into adulthood. At the no-effect dose (45 mg/kg/day) for adverse effects on pre- and postnatal development, plasma exposure (AUC)  was approximately 5 times that in humans at the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a3c915d9-60a1-4178-bd9e-2f35aa92858a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2</content>
		     
	<content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4ecf19b3-8e2f-464c-8a20-ed41d682a50d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
                        <content styleCode="bold">
		     
	Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness  in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="41cca2b1-dd2f-4ccf-8557-cef334742ceb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
                        <content styleCode="bold">
		     
	Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_6_Renal_Impairment">
                     <id root="2e779319-449a-4f28-9d8d-78082a679153"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88828-9" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">6</content>
                        <content styleCode="bold">
		     
	Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>The renal route of elimination plays a minor role in the clearance of atogepant<content styleCode="italics"> [see Clinical Pharmacology </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. For episodic migraine, in patients with severe renal impairment (CLcr 15-29 mL/min) and in patients with end-stage renal disease (ESRD) (CLcr &lt;15 mL/min), the recommended dosage of QULIPTA is 10 mg once daily; in patients with ESRD undergoing intermittent dialysis, QULIPTA should preferably be taken after dialysis <content styleCode="italics">[see Dosage and Administration</content>
                           <content styleCode="italics"> (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>. For chronic migraine, avoid use of QULIPTA in patients with severe renal impairment and in patients with ESRD. No dose adjustment is recommended for patients with mild or moderate renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_7_Hepatic_Impairment">
                     <id root="fea961a1-d8c6-4b61-bb7e-075deb0c62c9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88829-7" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">7</content>
		     
	<content styleCode="bold">Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment <content styleCode="italics">[see </content>
                           <content styleCode="italics">Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">) and </content>
                           <content styleCode="italics">Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.  </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="94c2e99b-0f37-46f5-8288-2456efbddbb2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
		     
	<content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>The active ingredient of QULIPTA is atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of atogepant is (3’<content styleCode="italics">S</content>)-<content styleCode="italics">N</content>-[(3<content styleCode="italics">S</content>,5<content styleCode="italics">S</content>,6<content styleCode="italics">R</content>)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2’-oxo-1’,2’,5,7-tetrahydrospiro[cyclopenta[<content styleCode="italics">b</content>]pyridine-6,3’-pyrrolo[2,3-<content styleCode="italics">b</content>]pyridine]-3-carboxamide, and it has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>The molecular formula is C<sub>29</sub>H<sub>2</sub>
                     <sub>3</sub>F<sub>6</sub>N<sub>5</sub>O<sub>3</sub> and molecular weight is 603.5. Atogepant is a white to off-white powder. It is freely soluble in ethanol, soluble in methanol, sparingly soluble in acetone, slightly soluble in acetonitrile, and practically insoluble in water.</paragraph>
                  <paragraph>QULIPTA is available as tablets for oral administration containing 10 mg, 30 mg, or 60 mg atogepant. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>The active ingredient of TRADENAME is atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of atogepant is (S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide and has the following structural formula:</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="aad6bf2c-3ed4-4055-9b02-075d8daba2de"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
		     
	<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250321"/>
               <component>
                  <section>
                     <id root="1e37027c-f364-43dc-adcd-17df93f85b2a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
		     
	<content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="626aeb18-3bb6-4bbb-b9ee-390953ffbfaa"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2</content>
                        <content styleCode="bold">
		     
	Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a dose 5 times the maximum recommended daily dose, QULIPTA does not prolong the QT interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="deadeb9f-aee8-4a33-9dfc-aad72740b611"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
		     
	<content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following oral administration of QULIPTA, atogepant is absorbed with peak plasma concentrations  at approximately 1 to 2 hours. Atogepant displays dose-proportional pharmacokinetics up to 170 mg per day (approximately 3 times the highest recommended dosage), with no accumulation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>When QULIPTA was administered with a high-fat meal, the food effect was not significant (AUC and C<sub>max</sub> were reduced by approximately 18% and 22%, respectively, with no effect on median time to maximum atogepant plasma concentration). QULIPTA was administered without regard to food in clinical efficacy studies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Plasma protein binding of atogepant was not concentration-dependent in the range of 0.1 to 10 µM; the unbound fraction of atogepant was approximately 4.7% in human plasma. The mean apparent volume of distribution of atogepant (Vz/F) after oral administration is approximately 292 L<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Atogepant is eliminated mainly through metabolism, primarily by CYP3A4. The parent compound (atogepant), and a glucuronide conjugate metabolite (M23) were the most prevalent circulating components in human plasma. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>The elimination half-life of atogepant is approximately 11 hours. The mean apparent oral clearance (CL/F) of atogepant is approximately 19 L/hr. Following single oral dose of 50 mg <sup>14</sup>C-atogepant to healthy male subjects, 42% and 5% of the dose was recovered as unchanged atogepant in feces and urine, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific</content>
                           <content styleCode="underline"> Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment </content>
                        </paragraph>
                        <paragraph>The renal route of elimination plays a minor role in the clearance of atogepant. Based on a population pharmacokinetic analysis, there is no significant difference in the pharmacokinetics of atogepant in patients with mild or moderate renal impairment (CLcr 30-89 mL/min) relative to those with normal renal function (CLcr &gt;90 mL/min). Patients with severe renal impairment or end-stage renal disease (ESRD; CLcr &lt;30 mL/min) have not been studied <content styleCode="italics">[see Dosage and Administration</content>
                           <content styleCode="italics"> (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics"> and Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Renal_Impairment">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment </content>
                        </paragraph>
                        <paragraph>In patients with pre-existing mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment, the total atogepant exposure was increased by 24%, 15%, and 38%, respectively. Due to a potential for liver injury in patients with severe hepatic impairment, avoid use of QULIPTA in patients with severe hepatic impairment<content styleCode="italics"> [see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_7_Hepatic_Impairment">8.7</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other Specific Populations</content>
                        </paragraph>
                        <paragraph>Based on a population pharmacokinetic analysis, age, sex, race, and body weight did not have a significant effect on the pharmacokinetics (C<sub>max</sub> and AUC) of atogepant. Therefore, no dose adjustments are warranted based on these factors.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>Enzymes</paragraph>
                        <paragraph>In vitro, atogepant is not an inhibitor for CYPs 3A4, 1A2, 2B6, 2C8, 2C9, 2C19, or 2D6 at clinically relevant concentrations. Atogepant does not inhibit MAO-A or UGT1A1 at clinically relevant concentrations. Atogepant is not anticipated to be a clinically significant perpetrator of drug-drug interactions through CYP450s, MAO-A, or UGT1A1 inhibition.</paragraph>
                        <paragraph>Atogepant is not an inducer of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations. </paragraph>
                        <paragraph>Transporters</paragraph>
                        <paragraph>Atogepant is a substrate of P-gp, BCRP, OATP1B1, OATP1B3, and OAT1. Dose adjustment for concomitant use of QULIPTA with inhibitors of OATP is recommended based on a clinical interaction study with a OATP inhibitor<content styleCode="italics"> [see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Coadministration of atogepant with BCRP and/or P-gp inhibitors is not expected to increase the exposure of atogepant. Atogepant is not a substrate of OAT3, OCT2, or MATE1.</paragraph>
                        <paragraph>Atogepant is not an inhibitor of P-gp, BCRP, OAT1, OAT3, NTCP, BSEP, MRP3, or MRP4 at clinically relevant concentrations. Atogepant is a weak inhibitor of OATP1B1, OATP1B3, OCT1, and MATE1. No clinical drug interactions are expected for atogepant as a perpetrator with these transporters. </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vivo Studies</content>
                        </paragraph>
                        <paragraph>CYP3A4 Inhibitors</paragraph>
                        <paragraph>Co-administration of QULIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a clinically significant increase (C<sub>max</sub> by 2.15-fold and AUC by 5.5-fold) in the exposure of atogepant in healthy subjects <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_CYP3A4_Inhibitors">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>Physiologically based pharmacokinetic (PBPK) modeling suggested co-administration of QULIPTA with moderate or weak CYP3A4 inhibitors increase atogepant AUC by 1.7- and 1.1-fold, respectively. The changes in atogepant exposure when coadministered with weak or moderate CYP3A4 inhibitors are not expected to be clinically significant. </paragraph>
                        <paragraph>CYP3A4 Inducers</paragraph>
                        <paragraph>Co-administration of QULIPTA with rifampin, a strong CYP3A4 inducer, decreased atogepant AUC by 60% and C<sub>max</sub> by 30% in healthy subjects <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_2_CYP3A4_Inducers">7.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. No dedicated drug interaction studies were conducted to assess concomitant use with moderate CYP3A4 inducers. Moderate inducers of CYP3A4 can decrease atogepant exposure <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_2_CYP3A4_Inducers">7.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.  Co-administration of QULIPTA with topiramate, a weak inducer of CYP3A4, decreased atogepant mean steady-state AUC <sub>0-τ </sub>by 25% and mean steady-state C<sub>max</sub> by 24% in healthy subjects <content styleCode="italics">[</content>
                           <content styleCode="italics">see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_2_CYP3A4_Inducers">7.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>BCRP/OATP/P-gp Inhibitors</paragraph>
                        <paragraph>Co-administration of QULIPTA with single dose rifampin, an OATP inhibitor, increased atogepant AUC by 2.85-fold and C<sub>max</sub> by 2.23-fold in healthy subjects <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_3_OATP_Inhibitors">7.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>Co-administration of QULIPTA with quinidine, a P-gp inhibitor, increased atogepant AUC by 26% and C<sub>max</sub> by 4% in healthy subjects. The changes in atogepant exposure when co-administered with P-gp inhibitors are not expected to be clinically significant.</paragraph>
                        <paragraph>PBPK modeling suggests that co-administration of QULIPTA with BCRP inhibitors increases atogepant exposure by 1.2-fold. This increase is not expected to be clinically significant.</paragraph>
                        <paragraph>Other Drug Interaction Evaluations</paragraph>
                        <paragraph>Co-administration of QULIPTA with oral contraceptive components ethinyl estradiol and levonorgestrel, famotidine, esomeprazole, acetaminophen, naproxen, sumatriptan, or ubrogepant did not result in significant pharmacokinetic interactions for either atogepant or co-administered drugs. Co-administration of QULIPTA with topiramate did not result in clinically significant changes in the pharmacokinetics of topiramate.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3b9bf778-a6a7-417b-980f-a3a230dea479"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
                  <content styleCode="bold">
		     
	NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250321"/>
               <component>
                  <section>
                     <id root="471b97bf-ad83-4bc3-b927-54c43a053a9b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
                        <content styleCode="bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenicity</content>
                        </paragraph>
                        <paragraph>Atogepant was administered orally to mice (0, 5, 20, or 75 mg/kg/day in males; 0, 5, 30, 160 mg/kg/day in females) and rats (0, 10, 20, or 100 mg/kg in males; 0, 25, 65, or 200 mg/kg in females) for up to 2 years. There was no evidence of drug-related tumors in either species. Plasma exposures at the highest doses tested in mice and rats were approximately 8 and 20-35 times, respectively, that in humans at the maximum recommended human dose (MRHD) of 60 mg/day. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenicity</content>
                        </paragraph>
                        <paragraph>Atogepant was negative in in vitro (Ames, chromosomal aberration test in Chinese Hamster Ovary cells) and in vivo (rat bone marrow micronucleus) assays.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Oral administration of atogepant (0, 5, 20, or 125 mg/kg/day) to male and female rats prior to and during mating and continuing in females to Gestation Day 7 resulted in no adverse effects on fertility or reproductive performance. Plasma exposures (AUC) at the highest dose tested are approximately 15 times that in humans at the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_14_CLINICAL_STUDIES">
               <id root="2c6a6d44-f725-4fa7-9aa5-c601d403e036"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
                  <content styleCode="bold">
		     
	CLINICAL STUDIES</content>
               </title>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Figure 1: Change from Baseline in Monthly Migraine Days in Study 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Figure 2: Distribution of Change from Baseline in Mean Monthly Migraine Days by Treatment Group in Study 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000005">
                     <text>Chart, bar chart

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000006">
                     <text>Figure 5: Change from Baseline in Monthly Migraine Days in Study 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000007">
                     <text>Figure 6: Distribution of Change from Baseline in Mean Monthly Migraine Days by Treatment Group in Study 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section>
                     <id root="ca90e27a-1a13-46b1-9baa-cbecd92ea01e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1</content>
                        <content styleCode="bold">
		     
	Episodic Migraine</content>
                     </title>
                     <text>
                        <paragraph>The efficacy of QULIPTA for the preventive treatment of episodic migraine in adults was demonstrated in two randomized, multicenter, double-blind, placebo-controlled studies (Study 1 and Study 2). The studies enrolled patients with at least a 1-year history of migraine with or without aura, according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria.</paragraph>
                        <paragraph>In Study 1 (NCT03777059), 910 patients were randomized 1:1:1:1 to receive QULIPTA 10 mg (N = 222), QULIPTA 30 mg (N = 230), QULIPTA 60 mg (N = 235), or placebo (N = 223), once daily for 12 weeks. In Study 2 (NCT02848326), 652 patients were randomized 1:2:2:2 to receive QULIPTA 10 mg (N = 94), QULIPTA 30 mg (N = 185), QULIPTA 60 mg (N = 187), or placebo (N = 186), once daily for 12 weeks. In both studies, patients were allowed to use acute headache treatments (i.e., triptans, ergotamine derivatives, NSAIDs, acetaminophen, and opioids) as needed. The use of a concomitant medication that acts on the CGRP pathway was not permitted for either acute or preventive treatment of migraine. The studies excluded patients with myocardial infarction, stroke, or transient ischemic attacks within six months prior to screening.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 1</content>
                        </paragraph>
                        <paragraph>The primary efficacy endpoint was the change from baseline in mean monthly migraine days (MMD) across the 12-week treatment period. Secondary endpoints included the change from baseline in mean monthly headache days, the change from baseline in mean monthly acute medication use days, the proportion of patients achieving at least a 50% reduction from baseline in mean MMD (3-month average), the change from baseline in mean monthly Activity Impairment in Migraine-Diary (AIM-D) Performance of Daily Activities (PDA) domain scores, the change from baseline in mean monthly AIM-D Physical Impairment (PI) domain scores, across the 12-week treatment period, and the change from baseline at Week 12 for Migraine Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive (RFR) domain scores.  </paragraph>
                        <paragraph>The AIM-D evaluates difficulty with performance of daily activities (PDA domain) and physical impairment (PI domain) due to migraine, with scores ranging from 0 to 100. Higher scores indicate greater impact of migraine, and reductions from baseline indicate improvement. The MSQ v2.1 Role Function-Restrictive (RFR) domain score assesses how often migraine impacts function related to daily social and work-related activities over the past 4 weeks, with scores ranging from 0 to 100. Higher scores indicate lesser impact of migraine on daily activities, and increases from baseline indicate improvement.</paragraph>
                        <paragraph>Patients had a mean age of 42 years (range 18 to 73 years), 89% were female, 83% were White, 14% were Black, and 9% were of Hispanic or Latino ethnicity. The mean migraine frequency at baseline was approximately 8 migraine days per month and was similar across treatment groups. A total of 805 (88%) patients completed the 12-week double-blind study period. Key efficacy results of Study 1 are summarized in Table 3. </paragraph>
                        <table>
                           <caption>Table 3: Efficacy Endpoints in Study 1</caption>
                           <col width="170"/>
                           <col width="161"/>
                           <col width="161"/>
                           <col width="161"/>
                           <col width="81"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <br/>
                                    <content styleCode="bold">10 mg</content>
                                    <br/>
                                    <content styleCode="bold">N=</content>
                                    <content styleCode="bold">214</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <br/>
                                    <content styleCode="bold">30 mg</content>
                                    <br/>
                                    <content styleCode="bold">N=</content>
                                    <content styleCode="bold">223</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <br/>
                                    <content styleCode="bold">60 mg</content>
                                    <br/>
                                    <content styleCode="bold">N=</content>
                                    <content styleCode="bold">222</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">N=</content>
                                    <content styleCode="bold">214</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">Monthly Migraine Days</content>
                                    <content styleCode="bold"> (MMD) across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">Monthly Headache Days</content>
                                    <content styleCode="bold"> across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">Monthly Acute Medication Use Days</content>
                                    <content styleCode="bold"> across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">≥ 50% </content>
                                    <content styleCode="bold">MMD</content>
                                    <content styleCode="bold"> Responders </content>
                                    <content styleCode="bold">across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">% Responders</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">56</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">59</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">61</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">32</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">MSQ</content>
                                    <content styleCode="bold"> v2.1 RFR</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Domain* at week 12</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">44.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">44.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">46.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">46.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">AIM-D </content>
                                    <content styleCode="bold">PDA Domain** across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-7.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-8.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-9.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NS<sup>†</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">AIM-D P</content>
                                    <content styleCode="bold">I Domain*** across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-5.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NS<sup>†</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.002</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">* Migraine Specific Quality of Life Questionnaire version 2.1 Role Function-Restrictive domain score<br/>** Activity Impairment in Migraine-Diary Performance of Daily Activities domain score<br/>*** Activity Impairment in Migraine-Diary Physical Impairment domain score<br/>
                                    <sup>†</sup>Not statistically significant (NS)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#Figure1new">Figure 1</linkHtml> shows the mean change from baseline in MMD in Study 1. Patients treated with QULIPTA had greater mean decreases from baseline in MMD across the 12-week treatment period compared to patients who received placebo. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">1</content>
                           <content styleCode="bold">:</content>
                           <content styleCode="bold"> Change from Baseline in Monthly Migraine Days in Study 1</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure1new" referencedObject="MM03000002"/>
                        </paragraph>
                        <paragraph>
                           <linkHtml href="#Figure2new">Figure 2</linkHtml> shows the distribution of change from baseline in mean MMD across the 12-week treatment period, in 2-day increments, by treatment group. A treatment benefit over placebo for all doses of QULIPTA is seen across a range of mean changes from baseline in MMD.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">2</content>
                           <content styleCode="bold">:</content>
                           <content styleCode="bold"> Distribution of Change from Baseline in Mean Monthly Migraine Days by Treatment Group in Study 1</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure2new" referencedObject="MM03000003"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 2</content>
                        </paragraph>
                        <paragraph>The primary efficacy endpoint was the change from baseline in mean monthly migraine days across the 12-week treatment period.</paragraph>
                        <paragraph>Patients had a mean age of 40 years (range: 18 to 74 years), 87% were female, 76% were White, 20% were Black, and 15% were of Hispanic or Latino ethnicity. The mean migraine frequency at baseline was approximately 8 migraine days per month. A total of 541 (83%) patients completed the 12-week double-blind study period.</paragraph>
                        <paragraph>In Study 2, there was a significantly greater reduction in mean monthly migraine days across the 12-week treatment period in all three QULIPTA treatment groups, compared with placebo, as summarized in Table 4. </paragraph>
                        <table>
                           <caption>Table 4: Efficacy Endpoints in Study 2</caption>
                           <col width="240"/>
                           <col width="108"/>
                           <col width="108"/>
                           <col width="108"/>
                           <col width="84"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <br/>
                                    <content styleCode="bold">10 mg</content>
                                    <br/>
                                    <content styleCode="bold">N=92</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <br/>
                                    <content styleCode="bold">30 mg</content>
                                    <br/>
                                    <content styleCode="bold">N=182</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA</content>
                                    <br/>
                                    <content styleCode="bold">60 mg</content>
                                    <br/>
                                    <content styleCode="bold">N=177</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">N=178</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">Monthly Migraine Days (MMD) across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.024</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.039</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.039</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">
                                    <content styleCode="bold">Monthly Headache Days across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-0.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.024</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.039</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.039</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#Figure3">Figure 3</linkHtml> shows the mean change from baseline in MMD in Study 2. Patients treated with QULIPTA had greater mean decreases from baseline in MMD across the 12-week treatment period compared to patients who received placebo. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Change from Baseline in Monthly Migraine Days in Study 2</content>
                        </paragraph>
                        <paragraph> <renderMultiMedia ID="Figure3" referencedObject="MM03000004"/>
                        </paragraph>
                        <paragraph>
                           <linkHtml href="#figure4">Figure 4</linkHtml> shows the distribution of change from baseline in mean MMD across the 12-week treatment period, in 2-day increments, by treatment group. A treatment benefit over placebo for all doses of QULIPTA is seen across a range of mean changes from baseline in MMD.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 4: Distribution of Change from Baseline in Mean Monthly Migraine Days by Treatment Group in Study 2</content>
                        </paragraph>
                        <paragraph> <renderMultiMedia ID="figure4" referencedObject="MM03000005"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="39afafb3-3f22-4b86-94e0-f547933dbb76"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2</content>
                        <content styleCode="bold">
		     
	Chronic Migraine</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study </content>
                           <content styleCode="underline">3</content>
                        </paragraph>
                        <paragraph>The efficacy of QULIPTA for the preventive treatment of chronic migraine in adults was demonstrated in a randomized, multicenter, double-blind, placebo-controlled study (Study 3). The study enrolled patients with at least a 1-year history of chronic migraine, according to the ICHD-3 diagnostic criteria. </paragraph>
                        <paragraph>Study 3 (NCT03855137) included randomization of patients to QULIPTA 60 mg once daily (N = 262) or placebo (N = 259) for 12 weeks. A subset of patients (11%) was allowed to use one concomitant migraine preventive medication. Patients were allowed to use acute headache treatments (i.e., triptans, ergotamine derivatives, NSAIDs, acetaminophen, and opioids) as needed. Patients with medication overuse headache also were enrolled. The use of a concomitant medication that acts on the CGRP pathway was not permitted for either acute or preventive treatment of migraine. The study excluded patients with myocardial infarction, stroke, or transient ischemic attacks within six months prior to screening. </paragraph>
                        <paragraph>The primary efficacy endpoint was the change from baseline in mean MMD across the 12-week treatment period. Secondary endpoints included the change from baseline in mean monthly headache days, the change from baseline in mean monthly acute medication use days, the proportion of patients achieving at least a 50% reduction from baseline in mean MMD (3-month average), the change from baseline in mean monthly AIM-D PDA domain scores, the change from baseline in mean monthly AIM-D PI domain scores, across the 12-week treatment period, and the change from baseline at Week 12 for MSQ v2.1 RFR domain scores. </paragraph>
                        <paragraph>Patients had a mean age of 42 years (range 18 to 74 years), 87% were female, 60% were White, 3% were Black, 36% were Asian, and 4% were of Hispanic or Latino ethnicity. The mean migraine frequency at baseline was approximately 19 migraine days per month and was similar across treatment groups. A total of 463 (89%) of these patients completed the 12-week double-blind study period. <br/>
                           <br/>Key efficacy results of Study 3 are summarized in <linkHtml href="#Table5">Table 5</linkHtml>.</paragraph>
                        <table ID="Table5">
                           <caption>Table 5: Efficacy Endpoints in Study 3</caption>
                           <col width="288"/>
                           <col width="162"/>
                           <col width="158"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">QULIPTA </content>
                                    <content styleCode="bold">60</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">mg</content>
                                    <content styleCode="bold"> QD</content>
                                    <br/>
                                    <content styleCode="bold">N=</content>
                                    <content styleCode="bold">256</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">N=</content>
                                    <content styleCode="bold">246</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Monthly Migraine Days</content>
                                    <content styleCode="bold"> (MMD) across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-5.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Monthly Headache Days</content>
                                    <content styleCode="bold"> across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-7.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-5.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-1.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Monthly Acute Medication Use Days</content>
                                    <content styleCode="bold"> across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-6.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-4.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">≥ 50% </content>
                                    <content styleCode="bold">MMD</content>
                                    <content styleCode="bold"> Responders </content>
                                    <content styleCode="bold">across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">% Responders</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">41</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">MSQ v2.1 RFR Domain* at week 12</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">43.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">43.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">AIM-D </content>
                                    <content styleCode="bold">PDA Domain** across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-12.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-9.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-3.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.001</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">AIM-D P</content>
                                    <content styleCode="bold">I Domain*** across 12 weeks</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Mean change from baseline</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-10.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-7.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Difference from placebo</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-2.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="italics">p</content>-value</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.003</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Migraine Specific Quality of Life Questionnaire version 2.1 Role Function-Restrictive domain score</paragraph>
                        <paragraph>** Activity Impairment in Migraine-Diary Performance of Daily Activities domain score</paragraph>
                        <paragraph>*** Activity Impairment in Migraine-Diary Physical Impairment domain score</paragraph>
                        <paragraph>
                           <linkHtml href="#Figure5">Figure 5</linkHtml> shows the mean change from baseline in MMD in Study 3. Patients treated with QULIPTA had greater mean decreases from baseline in MMD across the 12-week treatment period compared to patients who received placebo. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure</content>
                           <content styleCode="bold"> 5</content>
                           <content styleCode="bold">: Change from Baseline in Monthly Migraine Days in Study 3</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure5" referencedObject="MM03000006"/>
                        </paragraph>
                        <paragraph>
                           <linkHtml href="#Figure6">Figure 6</linkHtml> shows the distribution of change from baseline in mean MMD across the 12-week treatment period, in 2-day increments, by treatment group. A treatment benefit of QULIPTA over placebo is seen across a range of mean changes from baseline in MMD.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure</content>
                           <content styleCode="bold"> 6</content>
                           <content styleCode="bold">: Distribution of Change from Baseline in Mean Monthly</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">Migraine</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">Days</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">by</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">Treatment Group in Study 3</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure6" referencedObject="MM03000007"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4cb68e22-2950-42f2-a053-00640d617c72"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
		     
	<content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <effectiveTime value="20250321"/>
               <component>
                  <section>
                     <id root="ef31ef16-c9e6-4a5c-b753-3666ed918fc7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.1</content>
		     
	<content styleCode="bold">How Supplied</content>
                     </title>
                     <text>
                        <paragraph>QULIPTA 10 mg is supplied as white to off-white, round biconvex tablets debossed with “A” and “10” on one side in the following packaging presentations:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bottle of 30, NDC: 0074-7095-30</item>
                        </list>
                        <paragraph>QULIPTA 30 mg is supplied as white to off-white, oval biconvex tablets debossed with “A30” on one side in the following packaging presentations:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bottle of 30, NDC: 0074-7096-30</item>
                        </list>
                        <paragraph>QULIPTA 60 mg is supplied as white to off-white, oval biconvex tablets debossed with “A60” on one side in the following packaging presentations:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bottle of 30, NDC: 0074-7094-30</item>
                        </list>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7b0f8a25-ebb9-4d02-938c-fc2d76ad14fd"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="44425-7" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>
                        <content styleCode="bold">16.2</content>
		     
	<content styleCode="bold">Storage and Handling</content>
                     </title>
                     <text>
                        <paragraph>Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F) <content styleCode="italics">[</content>see <content styleCode="italics">USP Controlled Room Temperature</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8d3e7540-159e-425e-b249-888c9ebc064d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
		     
	<content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#PatientInformation">Patient Information</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions </content>
                  </paragraph>
                  <paragraph>Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur with QULIPTA. Advise patients to discontinue QULIPTA and seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#hyperlink5_1">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypertension</content>
                  </paragraph>
                  <paragraph>Inform patients that hypertension can develop or pre-existing hypertension can worsen with QULIPTA, and that they should contact their healthcare providers if they experience elevation in their blood pressure <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Hypertension">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Raynaud’s Phenomenon</content>
                  </paragraph>
                  <paragraph>Inform patients that Raynaud’s phenomenon can develop or worsen with QULIPTA. Advise patients to discontinue QULIPTA and contact their healthcare provider if they experience signs or symptoms of Raynaud’s phenomenon <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_3_Raynaud_s_Phenomenon">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Inform patients that QULIPTA may interact with certain other drugs, and that dosage modifications of QULIPTA may be recommended when used with some other drugs. Advise patients to report to their healthcare provider the use of any other prescription medications, over-the-counter medications, herbal products, or grapefruit juice <content styleCode="italics">[</content>
                     <content styleCode="italics">see Dosage and Administration</content>
                     <content styleCode="italics"> (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>
                     <content styleCode="italics"> and Drug Interactions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_7_1_CYP3A4_Inhibitors">7.1</linkHtml>
                     </content>
                     <content styleCode="italics">, </content>
                     <content styleCode="italics">
                        <linkHtml href="#_7_2_CYP3A4_Inducers">7.2</linkHtml>
                     </content>
                     <content styleCode="italics">, </content>
                     <content styleCode="italics">
                        <linkHtml href="#_7_3_OATP_Inhibitors">7.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Manufactured for:<br/>AbbVie Inc.<br/>North Chicago, IL 60064</paragraph>
                  <paragraph>© 2025 AbbVie. All rights reserved.</paragraph>
                  <paragraph>
                     <br/>QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.<br/>20091381  March 2025</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="6218f8b2-0ff2-4938-a3de-e46e86c5a1cc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table ID="PatientInformation">
                     <col width="353"/>
                     <col width="353"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">
                                 <sup>®</sup>
                              </content> <content styleCode="bold">(</content>
                              <content styleCode="bold">kew-LIP-tah</content>
                              <content styleCode="bold">)</content>
                              <br/>(atogepant)<br/>tablets, for oral use</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What is </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>QULIPTA is a prescription medicine used for the preventive treatment of migraine in adults.</item>
                              </list>It is not known if QULIPTA is safe and effective in children.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">Do not take QULIPTA if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have had an allergic reaction to atogepant or any ingredients in QULIPTA. See the end of this Patient Information leaflet for a complete list of ingredients in QULIPTA.  </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">Before you take </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold"> tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have high blood pressure.<br/>
                                 </item>
                                 <item>have circulation problems in your fingers and toes.<br/>
                                 </item>
                                 <item>have kidney problems or are on dialysis.<br/>
                                 </item>
                                 <item>have liver problems. <br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if QULIPTA will harm your unborn baby.<br/>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if QULIPTA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking QULIPTA.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">Keep a list of medicines you take to show to your healthcare provider or pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">How should I take </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take QULIPTA by mouth with or without food.<br/>
                                 </item>
                                 <item>Take QULIPTA exactly as your healthcare provider tells you to take it.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What are the possible side effects of </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <content styleCode="bold">QULIPTA can cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Allergic (hypersensitivity) reactions, including anaphylaxis: </content>Serious allergic reactions can happen when you take QULIPTA or days after. Stop taking QULIPTA and get emergency medical help right away if you get any of the following symptoms, which may be part of a serious allergic reaction: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
		     
	
		     
	• swelling of the face, lips, or tongue<br/>
		     
	
		     
	• trouble breathing<br/>
		     
	
		     
	• rash</td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>itching<br/>
                                 </item>
                                 <item>hives</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">High blood pressure:</content> High blood pressure or worsening of high blood pressure can happen when you take QULIPTA. Contact your healthcare provider if you have an increase in blood pressure.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Raynaud’s phenomenon:</content> A type of circulation problem can worsen or happen when you take QULIPTA. Raynaud’s phenomenon can lead to your fingers or toes feeling numb, cool, or painful, or changing color from pale, to blue, to red. Contact your healthcare provider if these symptoms occur.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <content styleCode="bold">The most common side effects of </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">include</content>
                              <content styleCode="bold">:</content> nausea, constipation, and fatigue/sleepiness. <br/>These are not all of the possible side effects of QULIPTA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">How should I store </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store QULIPTA at room temperature between 68ºF to 77ºF (20ºC to 25ºC).</item>
                              </list>
                              <content styleCode="bold">Keep </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold"> and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">General information about the safe and effective use of </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use QULIPTA for a condition for which it was not prescribed. Do not give QULIPTA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about QULIPTA that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What are the ingredients in </content>
                              <content styleCode="bold">QULIPTA</content>
                              <content styleCode="bold">? </content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> atogepant<br/>
                              <content styleCode="bold">Inactive ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.<br/>         <br/>Manufactured for:<br/>AbbVie Inc.<br/>North Chicago, IL 60064<br/>© 2025 AbbVie. All rights reserved.<br/>QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration                                 Revised:  3/2025</paragraph>
                  <paragraph>20091381</paragraph>
               </text>
               <effectiveTime value="20250321"/>
            </section>
         </component>
         <component>
            <section>
               <id root="16b4c043-7129-4415-b17b-25e7b0ea79c7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 0074-<content styleCode="bold">7095</content>-30<br/>Rx Only<br/>
                     <content styleCode="bold">QULIPTA</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <br/>(atogepant) tablets<br/>
                     <content styleCode="bold">10 mg</content>
                     <br/>
                     <br/>Contains 30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000008"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM02000008">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0074-7095-30
Rx Only
QULIPTA®
(atogepant) tablets
10 mg

Contains 30 Tablets
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4680a7f0-a5dd-4547-9bf1-b35c0f27714f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 0074-<content styleCode="bold">7096</content>-30<br/>Rx Only<br/>
                     <content styleCode="bold">QULIPTA</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <br/>(atogepant) tablets<br/>
                     <br/>
                     <content styleCode="bold">30 mg</content>
                     <br/>Contains 30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000009"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM02000009">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0074-7096-30
Rx Only
QULIPTA®
(atogepant) tablets

30 mg
Contains 30 Tablets
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="10567dc7-af93-4cd3-bb1c-2f34043fa57c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 0074-<content styleCode="bold">7094</content>-30<br/>Rx Only<br/>
                     <content styleCode="bold">QULIPTA</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <br/>(atogepant) tablets<br/>
                     <br/>
                     <content styleCode="bold">60 mg</content>
                     <br/>Contains 30 Tablets</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200000A"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="MM0200000A">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0074-7094-30
Rx Only
QULIPTA®
(atogepant) tablets

60 mg
Contains 30 Tablets
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="qulipta-0a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>